Key Points
- CFO Aaron Rosenberg sold 1,157 BeOne Medicines shares for approximately $361,805 at an average price of $312.71. The sale was made to cover tax withholding related to vested equity awards, rather than indicating a bearish investment decision.
- BeOne Medicines reported quarterly EPS of $2.05, exceeding the $1.40 consensus estimate. Analysts expect the company to generate approximately $5.93 in EPS for the full year.
- Institutional investors remain active, with several firms initiating or expanding positions; institutions and hedge funds now own 48.55% of the stock. Analyst sentiment is generally favorable, with a “Moderate Buy” consensus and an average price target of $394.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Aaron Rosenberg also recently made the following trade(s):
- On Thursday, June 11th, Aaron Rosenberg sold 631 shares of BeOne Medicines stock. The shares were sold at an average price of $257.74, for a total transaction of $162,633.94.
BeOne Medicines Price Performance
Shares of ONC opened at $327.53 on Thursday. The company's 50-day moving average is $294.53 and its 200-day moving average is $308.67. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The firm has a market capitalization of $35.94 billion, a PE ratio of 73.27 and a beta of 0.49. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post 5.93 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE bought a new position in shares of BeOne Medicines during the second quarter worth approximately $67,657,000. Man Group plc bought a new stake in shares of BeOne Medicines in the second quarter valued at approximately $59,031,000. BNP Paribas Financial Markets bought a new stake in shares of BeOne Medicines in the second quarter valued at approximately $38,337,000. First Trust Advisors LP grew its position in BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company's stock worth $71,696,000 after buying an additional 115,601 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in BeOne Medicines during the second quarter worth approximately $26,034,000. Institutional investors and hedge funds own 48.55% of the company's stock.
Key Stories Impacting BeOne Medicines
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
- Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
- Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
- Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
- Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Zacks Research lowered BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 3rd. Barclays reduced their price target on BeOne Medicines from $409.00 to $403.00 and set an "overweight" rating for the company in a research note on Tuesday, July 14th. Guggenheim upped their price objective on BeOne Medicines from $410.00 to $420.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BeOne Medicines in a report on Friday, July 17th. Finally, Nomura upgraded BeOne Medicines to a "strong-buy" rating in a research report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, BeOne Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $394.00.
Read Our Latest Stock Report on BeOne Medicines
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
